Benzylic Dehydroxylation of Echinocandin antifungal drugs restores efficacy against resistance conferred by mutated Glucan Synthase [PDF]
, 2022 Each year, infections caused by fungal pathogens claim the lives of about 1.6 million people and affect the health of over a billion people worldwide.
Carmeli, Shmuel +7 more
core +1 more source
Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Fungal cell wall : An underexploited target for antifungal therapies [PDF]
, 2021 Funding: The authors would like to acknowledge support from the University of Aberdeen and Abia State University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer ...
Ibe, Chibuike, Munro, Carol
core +1 more source
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. Rezafungin has potent in vitro activity against Candida albicans and Candida glabrata , including ...
Lakota, Elizabeth A. +3 more
openaire +2 more sources
Guideline adherence and survival of patients with candidaemia in Europe:results from the ECMM Candida III multinational European observational cohort study [PDF]
, 2023 Background: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is ...
core +6 more sources
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy [PDF]
Blood Purification, 2018 <b><i>Background/Aims:</i></b> To determine adsorption and transmembrane clearances (CL<sub>TM</sub>) of rezafungin, a novel long-acting echinocandin, in continuous venovenous hemofiltration (CVVH). <b><i>Methods:</i></b> A validated ex vivo bovine blood CVVH model using polysulfone and AN69 ...
Soo Min Jang +2 more
openaire +2 more sources
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
Advances in the Treatment of Invasive Fungal Disease [PDF]
, 2023 With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang +2 more
core +1 more source
Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia [PDF]
Biology of Blood and Marrow Transplantation, 2019 Background The risk of Pneumocystis pneumonia often warrants antifungal prophylaxis for bone marrow and solid organ transplantation patients. However, complications such as myelosuppression, nephrotoxicity, and intolerance with the existing standard, TMP/SMX, may hinder or interrupt prophylaxis. Rezafungin (RZF) is a novel echinocandin in development
Melanie Cushion, Alan Ashbaugh
openaire +1 more source
Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans
Antimicrobial Agents and Chemotherapy, 2022 Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus , and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [
Voon Ong +4 more
openaire +2 more sources